Zealand Pharma A/S (OTCMKTS:ZLDPF) and Aurinia Pharmaceuticals (NASDAQ:AUPH) Financial Survey

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Zealand Pharma A/S (OTCMKTS:ZLDPF) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Analyst Recommendations

This is a summary of current recommendations for Aurinia Pharmaceuticals and Zealand Pharma A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0	3	3	1	2.71
Zealand Pharma A/S	0	8	1	2	2.45

Aurinia Pharmaceuticals presently has a consensus price target of $17.75, indicating a potential upside of 5.28%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Zealand Pharma A/S.

Volatility & Risk

Aurinia Pharmaceuticals has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.

Profitability

This table compares Aurinia Pharmaceuticals and Zealand Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Zealand Pharma A/S	58.86%	17.56%	16.17%

Insider & Institutional Ownership

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Aurinia Pharmaceuticals and Zealand Pharma A/S”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05 million	7.93	$287.20 million	$2.29	7.36
Zealand Pharma A/S	$1.40 billion	1.74	$977.29 million	$6.03	5.62

Zealand Pharma A/S has higher revenue and earnings than Aurinia Pharmaceuticals. Zealand Pharma A/S is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Aurinia Pharmaceuticals beats Zealand Pharma A/S on 11 of the 15 factors compared between the two stocks.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.